Pathogenesis and Management of Sarcopenia

Overview

Journal Clin Geriatr Med

Specialty Geriatrics

Date 2016 Nov 26

PMID 27886695

Citations 222

Authors

Robinder J S Dhillon

Sarfaraz Hasni

Affiliations

Soon will be listed here.

Abstract

Sarcopenia represents a loss of muscle strength and mass in older individuals. Sarcopenia in the elderly has now become a major focus of research and public policy debate due to its impact on morbidity, mortality, and health care expenditure. Despite its clinical importance, sarcopenia remains under-recognized and poorly managed in routine clinical practice. This is, in part, due to a lack of available diagnostic testing and uniform diagnostic criteria. The management of sarcopenia is primarily focused on physical therapy for muscle strengthening and gait training. There are no pharmacologic agents for the treatment of sarcopenia.

Citing Articles

The evidence and impact of deprescribing on sarcopenia parameters: a systematic review.

Ibrahim K, Cox N, Lim S, Radcliffe E, Lundby C, Prokopidis K BMC Geriatr. 2025; 25(1):158.

PMID: 40055633 PMC: 11887267. DOI: 10.1186/s12877-025-05819-7.

The effect of pre-existing sarcopenia on outcomes of critically ill patients treated for COVID-19.

Bradier T, Grigioni S, Savoye-Collet C, Beduneau G, Carpentier D, Girault C J Crit Care Med (Targu Mures). 2025; 11(1):33-43.

PMID: 40017479 PMC: 11864067. DOI: 10.2478/jccm-2024-0045.

Are strategies to increase muscle mass and strength as effective in people with type 2 diabetes?.

Al-Awadi A, Gray S, Al-Ozairi E Rev Endocr Metab Disord. 2025; .

PMID: 39998784 DOI: 10.1007/s11154-025-09947-8.

FOXO regulation of TXNIP induces ferroptosis in satellite cells by inhibiting glutathione metabolism, promoting Sarcopenia.

Maimaiti Y, Abulitifu M, Ajimu Z, Su T, Zhang Z, Yu Z Cell Mol Life Sci. 2025; 82(1):81.

PMID: 39982519 PMC: 11845654. DOI: 10.1007/s00018-025-05592-1.

Muscular TOR knockdown and endurance exercise ameliorate high salt and age-related skeletal muscle degradation by activating the MTOR-mediated pathway.

Wang S, Wen D, Gao Y, Wang J, Ma X PLoS One. 2025; 20(1):e0311159.

PMID: 39841657 PMC: 11753686. DOI: 10.1371/journal.pone.0311159.

References

Goodpaster B, Park S, Harris T, Kritchevsky S, Nevitt M, Schwartz A . The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006; 61(10):1059-64. DOI: 10.1093/gerona/61.10.1059. View

Potsch M, Tschirner A, Palus S, von Haehling S, Doehner W, Beadle J . The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J Cachexia Sarcopenia Muscle. 2013; 5(2):149-58. PMC: 4053568. DOI: 10.1007/s13539-013-0125-7. View

Abellan van Kan G, Cderbaum J, Cesari M, Dahinden P, Fariello R, Fielding R . Sarcopenia: biomarkers and imaging (International Conference on Sarcopenia research). J Nutr Health Aging. 2011; 15(10):834-46. DOI: 10.1007/s12603-011-0365-1. View

Ryall J, Schertzer J, Lynch G . Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. Biogerontology. 2008; 9(4):213-28. DOI: 10.1007/s10522-008-9131-0. View

Fried L, Tangen C, Walston J, Newman A, Hirsch C, Gottdiener J . Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56(3):M146-56. DOI: 10.1093/gerona/56.3.m146. View

Durham W, Dillon E, Sheffield-Moore M . Inflammatory burden and amino acid metabolism in cancer cachexia. Curr Opin Clin Nutr Metab Care. 2008; 12(1):72-7. PMC: 2742684. DOI: 10.1097/MCO.0b013e32831cef61. View

Tomlinson B, Irving D . The numbers of limb motor neurons in the human lumbosacral cord throughout life. J Neurol Sci. 1977; 34(2):213-9. DOI: 10.1016/0022-510x(77)90069-7. View

Hughes V, Roubenoff R, Wood M, Frontera W, Evans W, Fiatarone Singh M . Anthropometric assessment of 10-y changes in body composition in the elderly. Am J Clin Nutr. 2004; 80(2):475-82. DOI: 10.1093/ajcn/80.2.475. View

Dingemans A, de Vos-Geelen J, Langen R, Schols A . Phase II drugs that are currently in development for the treatment of cachexia. Expert Opin Investig Drugs. 2014; 23(12):1655-69. DOI: 10.1517/13543784.2014.942729. View

10.

Cesari M, Fielding R, Pahor M, Goodpaster B, Hellerstein M, van Kan G . Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle. 2012; 3(3):181-90. PMC: 3424187. DOI: 10.1007/s13539-012-0078-2. View

11.

Stenholm S, Harris T, Rantanen T, Visser M, Kritchevsky S, Ferrucci L . Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008; 11(6):693-700. PMC: 2633408. DOI: 10.1097/MCO.0b013e328312c37d. View

12.

Muscaritoli M, Anker S, Argiles J, Aversa Z, Bauer J, Biolo G . Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr. 2010; 29(2):154-9. DOI: 10.1016/j.clnu.2009.12.004. View

13.

Relph W . Addressing the nutritional needs of older patients. Nurs Older People. 2016; 28(3):16-9. DOI: 10.7748/nop.28.3.16.s22. View

14.

Marcell T . Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci. 2003; 58(10):M911-6. DOI: 10.1093/gerona/58.10.m911. View

15.

Roth S, Ferrell R, Hurley B . Strength training for the prevention and treatment of sarcopenia. J Nutr Health Aging. 2000; 4(3):143-55. View

16.

Doherty T, Brown W . Age-related changes in the twitch contractile properties of human thenar motor units. J Appl Physiol (1985). 1997; 82(1):93-101. DOI: 10.1152/jappl.1997.82.1.93. View

17.

Cruz-Jentoft A, Baeyens J, Bauer J, Boirie Y, Cederholm T, Landi F . Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4):412-23. PMC: 2886201. DOI: 10.1093/ageing/afq034. View

18.

Sayer A . Sarcopenia the new geriatric giant: time to translate research findings into clinical practice. Age Ageing. 2014; 43(6):736-7. DOI: 10.1093/ageing/afu118. View

19.

Lynch G . Emerging drugs for sarcopenia: age-related muscle wasting. Expert Opin Emerg Drugs. 2004; 9(2):345-61. DOI: 10.1517/14728214.9.2.345. View

20.

Roubenoff R . Origins and clinical relevance of sarcopenia. Can J Appl Physiol. 2001; 26(1):78-89. DOI: 10.1139/h01-006. View